EU Commission Misses Chance To Lead On Drug Patent Settlements
The European Commission has published its annual report on the monitoring of patent settlements in Europe but has again failed to offer pharma firms the guidance and legal certainty they need.
You may also be interested in...
The Advocate General of the Court of Justice of the European Union has dismissed Spain’s second challenge to the unitary patent, offering more legal certainty for drug manufacturers and pointing the way towards reduced litigation costs.
The EC is scrutinizing pharma practices that may delay generic entry and advocating changes in the patent system.
Government officials investigate possible obstacles to competition in the drug industry, expect a preliminary report this fall.